Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,695,886
  • Shares Outstanding, K 127,274
  • Annual Sales, $ 829,250 K
  • Annual Income, $ 281,590 K
  • EBIT $ 476 M
  • EBITDA $ 562 M
  • 60-Month Beta 1.27
  • Price/Sales 7.99
  • Price/Cash Flow 16.45
  • Price/Book 22.99

Options Overview Details

View History
  • Implied Volatility 46.47% ( +4.41%)
  • Historical Volatility 44.51%
  • IV Percentile 89%
  • IV Rank 68.90%
  • IV High 58.43% on 10/27/23
  • IV Low 19.97% on 06/04/24
  • Put/Call Vol Ratio 0.02
  • Today's Volume 294
  • Volume Avg (30-Day) 410
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 10,448
  • Open Int (30-Day) 10,303

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 0.93
  • Number of Estimates 6
  • High Estimate 0.98
  • Low Estimate 0.89
  • Prior Year 0.69
  • Growth Rate Est. (year over year) +34.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
49.63 +4.31%
on 10/09/24
62.00 -16.50%
on 10/03/24
-7.47 (-12.61%)
since 09/20/24
3-Month
49.63 +4.31%
on 10/09/24
65.53 -21.00%
on 08/29/24
-2.27 (-4.20%)
since 07/19/24
52-Week
32.83 +57.69%
on 10/25/23
65.53 -21.00%
on 08/29/24
+16.61 (+47.24%)
since 10/20/23

Most Recent Stories

More News
Implied Volatility Surging for Halozyme Therapeutics (HALO) Stock Options

Investors in Halozyme Therapeutics, Inc. HALO need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 20, 2024 $17.5 Call had some of the highest implied...

HALO : 51.77 (-1.60%)
Global Cancer Rates Surge as Biotech Innovators Work on New Therapies

/CNW/ -- USA News Group – Cancer rates are rising globally, and the outlook is particularly concerning for men. A recent global study projects an 84% increase...

ONCY : 1.2600 (-6.67%)
ACLX : 90.28 (-6.79%)
ONC.TO : 1.76 (-4.86%)
GTHX : 7.15 (unch)
HALO : 51.77 (-1.60%)
SNY : 53.66 (-2.31%)
Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates

/CNW/ -- USA News Group – Pancreatic cancer is among the deadliest cancers, prompting researchers to focus on early detection to improve survival rates. Johns...

ONCY : 1.2600 (-6.67%)
HALO : 51.77 (-1.60%)
CADL : 5.84 (-3.63%)
MRUS : 51.60 (-2.07%)
RHHBY : 39.4000 (-0.40%)
ONC.TO : 1.76 (-4.86%)
Biotech Innovations Poised to Transform Pancreatic Cancer Treatment and Patient Outcomes

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – Pancreatic cancer is among the...

ONCY : 1.2600 (-6.67%)
ONC.TO : 1.76 (-4.86%)
RHHBY : 39.4000 (-0.40%)
HALO : 51.77 (-1.60%)
CADL : 5.84 (-3.63%)
MRUS : 51.60 (-2.07%)
Halozyme Therapeutics: Q2 Earnings Snapshot

Halozyme Therapeutics: Q2 Earnings Snapshot

HALO : 51.77 (-1.60%)
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

/CNW/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding...

ONCY : 1.2600 (-6.67%)
CADL : 5.84 (-3.63%)
AZN : 77.44 (-1.05%)
HALO : 51.77 (-1.60%)
JANX : 50.49 (+0.92%)
ONC.TO : 1.76 (-4.86%)
Rising Cancer Rates Drive Biotech Advancements Despite Political Hurdles

USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden’s “Cancer...

ONCY : 1.2600 (-6.67%)
ONC.TO : 1.76 (-4.86%)
CADL : 5.84 (-3.63%)
AZN : 77.44 (-1.05%)
HALO : 51.77 (-1.60%)
JANX : 50.49 (+0.92%)
Halozyme Therapeutics: Q1 Earnings Snapshot

Halozyme Therapeutics: Q1 Earnings Snapshot

HALO : 51.77 (-1.60%)
Halozyme Therapeutics: Q4 Earnings Snapshot

Halozyme Therapeutics: Q4 Earnings Snapshot

HALO : 51.77 (-1.60%)
Plexus, SunPower fall; Progress Software, Masonite International rise, Wednesday, 1/17/2024

Stocks that traded heavily or had substantial price changes on Wednesday: Plexus, SunPower fall; Progress Software, Masonite International rise

PLXS : 136.23 (-1.41%)
SPWR : 0.1228 (-5.47%)
BGFV : 2.08 (-3.70%)
PRGS : 65.38 (-0.80%)
HALO : 51.77 (-1.60%)
PI : 227.14 (+4.05%)
DOOR : 132.84 (+0.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Halozyme Therapeutics Inc. is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company's ENHANZE drug delivery technology helps in developing subcutaneous formulation of drugs. The company...

See More

Key Turning Points

3rd Resistance Point 53.86
2nd Resistance Point 53.32
1st Resistance Point 52.54
Last Price 51.77
1st Support Level 51.22
2nd Support Level 50.68
3rd Support Level 49.90

See More

52-Week High 65.53
Fibonacci 61.8% 53.04
Last Price 51.77
Fibonacci 50% 49.18
Fibonacci 38.2% 45.32
52-Week Low 32.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar